Jan 2026· Canadian Respiratory Journal· Vol 2026· 0 citations· 21 references
Medicine
TL;DR
Among children with MUMPP, higher WBC count, prolonged fever, pleural effusion, and higher CRP identify increased risk of NP, and decision curve analysis suggested net clinical benefit across relevant threshold probabilities.
Abstract
Objective This study aimed to identify factors that predict progression to necrotizing pneumonia (NP) in children with Mycoplasma pneumoniae pneumonia (MPP) who fail to respond to initial therapy and to develop a predictive model to support early clinical decision‐making. Methods We retrospectively analyzed clinical and laboratory data of children with macrolide‐unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) admitted to Tianjin Children’s Hospital from January 2021 to January 2025. MUMPP was defined as persistent fever (≥ 38.5°C, lasting ≥ 4 h/day) after ≥ 72 h of standardized intravenous macrolide therapy. Patients were classified into an observation group (n = 106, those who developed NP) and a control group (n = 130, those who did not). Independent predictors of NP were identified by multivariable logistic regression and incorporated into a nomogram. Model performance was evaluated using ROC analysis, calibration plots, and decision curve analysis. Results In multivariable analysis, increased white blood cell (WBC) count (OR = 2.484, 95% CI: 1.406–4.613), longer fever duration (OR = 1.618, 95% CI: 1.217–2.193), pleural effusion (OR = 3.955, 95% CI: 1.664–10.00), and elevated C‐reactive protein (CRP) (OR = 2.152, 95% CI: 1.547–3.074) were independently associated with NP among children with MPP after initial treatment failure. Calibration curves indicated close agreement between predicted and observed risks in both the derivation cohort (p = 0.588) and the validation cohort (p = 0.424). The model showed good discrimination, with an AUC of 0.848 (95% CI: 0.789–0.908) in the derivation cohort and 0.889 (95% CI: 0.815–0.963) in the validation cohort. Decision curve analysis suggested net clinical benefit across relevant threshold probabilities. Conclusion Among children with MUMPP, higher WBC count, prolonged fever, pleural effusion, and higher CRP identify increased risk of NP.
Objective To understand the clinical characteristics of severe and nonsevere Mycoplasma pneumoniae pneumonia (MPP) in children and analyze the risk factors for severe Mycoplasma pneumoniae pneumonia (SMPP), providing a basis for early clinical diagnosis and treatment of SMPP. Methods A retrospective analysis was conduc...
C. Fu, Xiang He, Cheng-Cheng Li et al.· Canadian Respiratory Journal· 0 citations
Background Mycoplasma pneumoniae pneumonia (MPP) remains a leading cause of community-acquired pneumonia in children, with respiratory failure occurring in 15%–20% of hospitalized cases. Despite advances in understanding MPP pathogenesis, validated tools for early prediction of respiratory failure are lacking. This stu...
Jiao Lian, Xi-Yao Si, Xiao-Long Li et al.· Frontiers in Pediatrics· 0 citations
Background
Mycoplasma pneumoniae carries a clinically important risk of a refractory course or the need for intensified corticosteroid therapy. No admission-day prediction tool has been validated to identify children at risk for either outcome.
Methods
Children admitted to a single tertiary centre with a diagnosis of...
Yue-Qian Li, Yi-Nan Shen, Xiao-Yu Shi et al.· Frontiers in Pediatrics· 0 citations
Objective This study sought to establish and externally validate an interpretable CT-based radiomics framework for early prediction of adverse disease progression in children with Mycoplasma pneumoniae pneumonia (MPP). Methods In this multicenter retrospective study, 419 children with MPP from three hospitals were assi...
Xiao-Yu Yao, Zheng-Fang Liu· Frontiers in Medicine· 0 citations
Omadacycline demonstrated considerable clinical efficacy even in patients who had failed initial quinolone therapy, and omadacycline may be an effective therapeutic option, particularly in patients with persistent fever after quinolone therapy.
Qiu-Ting Jiang, Xiao-Li Zhao, Yuan Zhu et al.· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.